Stockscreener 앱 받기
16.17
0.25%
0.04
시간 외 거래:
16.03
-0.14
-0.87%
전일 마감가:
$16.13
열려 있는:
$16.13
하루 거래량:
110.35K
Relative Volume:
1.30
시가총액:
$325.20M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.17%
1개월 성능:
+7.44%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$15.87
$16.83
1주일 범위
$15.05
$16.95
52주 변동 폭
$13.36
$17.50
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
LBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
16.17 | 362.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 개시 | Leerink Partners | Outperform |
| 2025-10-06 | 개시 | Piper Sandler | Overweight |
| 2025-10-06 | 개시 | Stifel | Buy |
Lb Pharmaceuticals Inc 주식(LBRX)의 최신 뉴스
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
LB Pharmaceuticals Inc Rings the Closing Bell - Nasdaq
LB Pharmaceuticals Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Novo-Backed MapLight Raises $258.9 Million in US IPO, Placement - Bloomberg.com
LB Pharmaceuticals Inc (LBRX) Recent Insider Transactions - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
LB Pharmaceuticals Inc (LBRX) Latest Press Releases & Corporate News - Yahoo
LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history - Yahoo! Finance Australia
Anna Eramo Net Worth (2025) - GuruFocus
Rebecca Luse Net Worth (2025) - GuruFocus
Zachary Prensky Net Worth (2025) - GuruFocus
LB Pharmaceuticals appoints Rawls as SVP of Regulatory Affairs - MSN
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs - GlobeNewswire
LB Pharmaceuticals appoints James Rawls as SVP of regulatory affairs By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Inc Appoints James Rawls as Senior Vice President of Regulatory Affairs - MarketScreener
LB Pharmaceuticals appoints James Rawls as SVP of regulatory affairs - Investing.com
LB Pharmaceuticals Inc's Quiet Period Set To End on October 21st (NASDAQ:LBRX) - MarketBeat
LB Pharmaceuticals Inc’s Quiet Period Set To End on October 21st (NASDAQ:LBRX) - Defense World
Analysts Set LB Pharmaceuticals Inc (NASDAQ:LBRX) PT at $30.50 - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Raised to Hold at Zacks Research - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Biopharma financings climb to $18.7B in the third quarter - BioWorld MedTech
Q3 Earnings Forecast for LBRX Issued By Leerink Partnrs - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Leerink Partnrs - Defense World
September biopharma financings jump 54% to $7.12B - BioWorld MedTech
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded at Leerink Partnrs - MarketBeat
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms - Sahm
Drug developer MapLight eyes $704.3 million valuation in US IPO - Reuters
LB Pharmaceuticals to Present Three Posters at 38th ECNP - GlobeNewswire
Leerink Partners Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $34 - 富途牛牛
Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential - TipRanks
Leerink Partners Initiates LB Pharmaceuticals at Outperform With $34 Price Target - MarketScreener
0.66 effect size in cognition: LB Pharma's LB‑102 shows dose‑dependent gains; 3 ECNP posters Oct 11-14 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Now Covered by Analysts at Leerink Partners - MarketBeat
LB Pharmaceuticals stock initiated at Outperform by Leerink Partners - Investing.com
Promising Prospects for LB Pharmaceuticals: Buy Rating Affirmed on LB-102’s Market Potential - TipRanks
Piper Sandler initiates coverage on LB Pharmaceuticals stock with Overweight rating - Investing.com
Stifel initiates coverage on LB Pharmaceuticals stock with Buy rating - Investing.com
LB Pharmaceuticals IncCommon Stock (Nasdaq:LBRX) Stock Quote - FinancialContent
LB Pharmaceuticals Appoints William Kane and Rekha Hemrajani To Board - citybiz
LB Pharmaceuticals adds two directors following Nasdaq debut By Investing.com - Investing.com Nigeria
LB Pharmaceuticals adds two directors following Nasdaq debut - Investing.com India
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - The Manila Times
Strategic Board Expansion: LB Pharmaceuticals Strengthens Leadership for Phase 3 Schizophrenia Drug Trial - Stock Titan
Scoop: Voltron Therapeutics plans IPO next year - Axios
Deep Track Capital, LP Acquires Significant Stake in LB Pharmaceuticals Inc - GuruFocus
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pha - GuruFocus
COMMODORE CAPITAL LP Acquires 1,225,000 Shares in LB Pharmaceuti - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in LB Pharmace - GuruFocus
Lb Pharmaceuticals Inc (LBRX) 재무 분석
Lb Pharmaceuticals Inc (LBRX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):